CF PharmTech, Inc. (HKG:2652)

Market Cap	8.04B
Revenue (ttm)	481.31M +23.9%
Net Income	2.77M
EPS	0.01
Shares Out	411.03M
PE Ratio	2,908.80
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	627,500
Average Volume	455,165
Open	18.80
Previous Close	19.62
Day's Range	18.10 - 19.99
52-Week Range	18.10 - 48.80
Beta	n/a
RSI	29.63
Earnings Date	Mar 30, 2026

About CF PharmTech

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 605
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2652

Financial Performance

In 2025, CF PharmTech's revenue was 432.52 million, a decrease of -28.83% compared to the previous year's 607.75 million. Earnings were 2.49 million, a decrease of -88.22%.

Financial numbers in CNY